Posts Tagged ‘CAR-T’

Right Turn: Genes are this season’s hottest trend

Author: Stacey Johnson, 10/20/17

In what feels like back-to-back news, the U.S. Food and Drug Administration (FDA) has approved two gene therapies for cancer. The actual announcements happened seven weeks apart, but for patients, manufacturers, investors and shareholders, it’s like Christmas – over and over again. As you probably know, Novartis’ Kymriah was approved at the end of August…Read more

Peter Zandstra and CCRM: Making cell therapies a commercial reality

Author: Guest, 01/31/17

Dr. Rohin Iyer is currently a Development Manager at GE Healthcare / CCRM. He did his PhD in Biomedical Engineering at the University of Toronto, and has been working in the field of stem cells and tissue engineering for over 12 years. He is an avid tweeter (follow @DrRohinIyer) on cell therapies and regenerative medicine. …Read more

Right Turn: Has cancer immunotherapy arrived?

Author: Stacey Johnson, 07/29/16

It was Science magazine’s 2013 breakthrough of the year and called a “turning point in cancer.” It even scored its own awareness month that year. Cancer immunotherapy – therapies that harness the power of a patient’s immune system to fight their disease – had officially arrived. Fast-forward three years and now companies are tripping over…Read more

What do car (and CAR) choices have to do with cell therapies?

Author: James Smith, 03/07/16

Post by James Smith and Mackenna Roberts. Ms. Roberts is an English-qualified lawyer, trained bioethicist and strategic adviser for the commercialization of emerging biomedical technologies and is widely published on how the law should govern cutting-edge medical therapies. She is an associate at IP Asset Partnership Ltd in London, IP consultant to IP Asset Ventures…Read more

Cell Therapy Deal Review: October

Author: Mark Curtis, 11/24/15

Welcome to your Cell Therapy Deal Review for the month of October. Lion Biotechnologies and Kite Pharma both made deals with the National Institutes of Health (NIH) that significantly expanded their respective pipelines. Kite also announced a research collaboration with Alpine Immune Sciences to enhance its CAR T portfolio with a novel transmembrane protein platform….Read more

Highlights from the 2015 “Business of Regenerative Medicine” course

Author: Guest, 08/27/15

. Nadia Houri is a Business Development Analyst with the Centre for Commercialization of Regenerative Medicine (CCRM).   Last month, I had the pleasure of attending The Business of Regenerative Medicine: Cells at Work course, hosted by Georgia Tech, in Atlanta. With two and a half very full days of lectures and networking opportunities, cells…Read more

Regenerative Medicine Deal Review: January

Author: Mark Curtis, 02/23/15

. Welcome to your deal review for the month of January. There was a mixed bag of news last month, which included financing activity, industry partnerships and research collaborations. The cell therapy tools industry was front and centre as NeoStem and Invetech struck up a deal to develop a closed, automated cell manufacturing unit for…Read more